Home › Companies › Fate Therapeutics, Inc. › 2025-2026
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Fate Therapeutics, Inc.’s Form 8-K, filed June 15, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 12, 2026: 6 items on Fate Therapeutics, Inc.’s Form 8-K, filed June 15, 2026: 3 elected · 3 passed (calculated).
Notable dissent: 1 other board item (23.5% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore Fate Therapeutics, Inc. in the interactive database Compare manager voting policies
These tallies are Fate Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 15, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Robert S. Epstein, M.D., M.S. | 59,332,820 | -- | -- | 1,717,842 | 26,083,760 | 97% | Elected | — |
| Elect Director: Karin Jooss, Ph.D. | 59,655,584 | -- | -- | 1,395,078 | 26,083,760 | 98% | Elected | — |
| Elect Director: Laura J. Hamill | 60,850,004 | -- | -- | 200,658 | 26,083,760 | 99.7% | Elected | — |
| (ii) Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. | 86,552,927 | 308,582 | 272,913 | -- | 0 | 99.6% | Passed (calculated) | — |
| (iii) Non-binding advisory vote on the compensation of the Company's named executive officers. | 59,168,689 | 1,808,669 | 73,304 | -- | 26,083,760 | 97% | Passed (calculated) | — |
| (iv) Approval of an amendment and restatement of the 2022 A&R Plan to increase the number of shares of Common Stock reserved for issuance thereunder. | 46,645,607 | 14,304,810 | 100,245 | -- | 26,083,760 | 77% | Passed (calculated) | — |
Source: Fate Therapeutics, Inc., Form 8-K, filed with the SEC on June 15, 2026 — read the filing on EDGAR.
See voting trends for Health Care companies, 2025-2026: shareholder support by sector and by company size.
140 asset managers disclosed a vote on at least one Fate Therapeutics, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 3 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Description as filed by funds: Election of Class I Directors: Karin Jooss, Ph.D.
Fate Therapeutics, Inc.’s own tally for this item (“Elect Director: Karin Jooss, Ph.D.”): 59,655,584 for, 1,395,078 withheld, per its Form 8-K filed June 15, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “All matters submitted to a vote of the Company's stockholders at the Annual Meeting were approved and all director nominees were elected.”
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 43 asset managers below reported 18,800,389 for, 119,786 withheld, 5 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,334,835 | 0 | 5 | 9,707 | For |
| BlackRock | 4,292,201 | 0 | 0 | 0 | For |
| Fidelity | 2,222,049 | 0 | 0 | 0 | For |
| BRUCE FUND INC | 789,188 | 0 | 0 | 0 | For |
| Charles Schwab | 756,976 | 0 | 0 | 0 | For |
| Invesco | 347,469 | 0 | 0 | 0 | For |
| Equitable | 190,328 | 0 | 0 | 109,540 | Mixed |
| TIAA | 271,483 | 0 | 0 | 0 | For |
| Dimensional | 255,844 | 0 | 0 | 0 | For |
| AQR | 194,978 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 185,000 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 177,479 | 0 | 0 | 0 | For |
| Goldman Sachs | 166,654 | 0 | 0 | 0 | For |
| Lincoln Financial | 78,044 | 0 | 0 | 0 | For |
| Northern Trust | 61,862 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 58,263 | 0 | 0 | 0 | For |
| Global X | 51,084 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 45,952 | 0 | 0 | 0 | For |
| Pacific Life | 43,851 | 0 | 0 | 0 | For |
| Nationwide | 35,680 | 0 | 0 | 0 | For |
| Thrivent | 33,153 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 25,500 | 0 | 0 | 0 | For |
| Voya | 22,502 | 0 | 0 | 0 | For |
| SEI | 18,600 | 0 | 0 | 0 | For |
| ProShares | 16,144 | 0 | 0 | 0 | For |
Showing the 25 largest of 43 asset managers. All 43 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
99.7% Majority: yes · of votes cast
Description as filed by funds: Election of Class I Directors: Laura J. Hamill
Fate Therapeutics, Inc.’s own tally for this item (“Elect Director: Laura J. Hamill”): 60,850,004 for, 200,658 withheld, per its Form 8-K filed June 15, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “All matters submitted to a vote of the Company's stockholders at the Annual Meeting were approved and all director nominees were elected.”
Support: 99.7% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 43 asset managers below reported 18,920,180 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,344,547 | 0 | 0 | 0 | For |
| BlackRock | 4,292,201 | 0 | 0 | 0 | For |
| Fidelity | 2,222,049 | 0 | 0 | 0 | For |
| BRUCE FUND INC | 789,188 | 0 | 0 | 0 | For |
| Charles Schwab | 756,976 | 0 | 0 | 0 | For |
| Invesco | 347,469 | 0 | 0 | 0 | For |
| Equitable | 299,868 | 0 | 0 | 0 | For |
| TIAA | 271,483 | 0 | 0 | 0 | For |
| Dimensional | 255,844 | 0 | 0 | 0 | For |
| AQR | 194,978 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 185,000 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 177,479 | 0 | 0 | 0 | For |
| Goldman Sachs | 166,654 | 0 | 0 | 0 | For |
| Lincoln Financial | 78,044 | 0 | 0 | 0 | For |
| Northern Trust | 61,862 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 58,263 | 0 | 0 | 0 | For |
| Global X | 51,084 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 45,952 | 0 | 0 | 0 | For |
| Pacific Life | 43,851 | 0 | 0 | 0 | For |
| Nationwide | 35,680 | 0 | 0 | 0 | For |
| Thrivent | 33,153 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 25,500 | 0 | 0 | 0 | For |
| Voya | 22,502 | 0 | 0 | 0 | For |
| SEI | 18,600 | 0 | 0 | 0 | For |
| ProShares | 16,144 | 0 | 0 | 0 | For |
Showing the 25 largest of 43 asset managers. All 43 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
97% Majority: yes · of votes cast
Description as filed by funds: Election of Class I Directors: Robert S. Epstein, M.D., M.S.
Fate Therapeutics, Inc.’s own tally for this item (“Elect Director: Robert S. Epstein, M.D., M.S.”): 59,332,820 for, 1,717,842 withheld, per its Form 8-K filed June 15, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “All matters submitted to a vote of the Company's stockholders at the Annual Meeting were approved and all director nominees were elected.”
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 43 asset managers below reported 18,558,811 for, 361,365 withheld, 4 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,330,131 | 0 | 4 | 14,412 | For |
| BlackRock | 4,292,201 | 0 | 0 | 0 | For |
| Fidelity | 2,222,049 | 0 | 0 | 0 | For |
| BRUCE FUND INC | 789,188 | 0 | 0 | 0 | For |
| Charles Schwab | 756,976 | 0 | 0 | 0 | For |
| Invesco | 347,469 | 0 | 0 | 0 | For |
| Equitable | 190,328 | 0 | 0 | 109,540 | Mixed |
| TIAA | 271,483 | 0 | 0 | 0 | For |
| Dimensional | 255,844 | 0 | 0 | 0 | For |
| AQR | 194,978 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 185,000 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 177,479 | 0 | 0 | 0 | For |
| Goldman Sachs | 0 | 0 | 0 | 166,654 | Withhold |
| Lincoln Financial | 78,044 | 0 | 0 | 0 | For |
| Northern Trust | 0 | 0 | 0 | 61,862 | Withhold |
| MASTER INVESTMENT PORTFOLIO | 58,263 | 0 | 0 | 0 | For |
| Global X | 51,084 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 45,952 | 0 | 0 | 0 | For |
| Pacific Life | 43,851 | 0 | 0 | 0 | For |
| Nationwide | 35,680 | 0 | 0 | 0 | For |
| Thrivent | 33,153 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 25,500 | 0 | 0 | 0 | For |
| Voya | 22,502 | 0 | 0 | 0 | For |
| SEI | 18,600 | 0 | 0 | 0 | For |
| ProShares | 16,144 | 0 | 0 | 0 | For |
Showing the 25 largest of 43 asset managers. All 43 are in the interactive database (link above).
77% Majority: yes · of votes cast
Description as filed by funds: TO APPROVE A PROPOSAL TO AMEND AND RESTATE THE COMPANY'S 2022 STOCK OPTION AND INCENTIVE PLAN TO INCREASE THE NUMBER OF SHARES OF COMMON STOCK RESERVED FOR ISSUANCE THEREUNDER.
Fate Therapeutics, Inc.’s own tally for this item (“(iv) Approval of an amendment and restatement of the 2022 A&R Plan to increase the number of shares of Common Stock reserved for issuance thereunder.”): 46,645,607 for, 14,304,810 against, per its Form 8-K filed June 15, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a majority of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 77% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 43 asset managers below reported 17,025,443 for, 1,894,736 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,334,784 | 9,762 | 0 | 0 | For |
| BlackRock | 4,292,201 | 0 | 0 | 0 | For |
| Fidelity | 2,222,049 | 0 | 0 | 0 | For |
| BRUCE FUND INC | 789,188 | 0 | 0 | 0 | For |
| Charles Schwab | 756,976 | 0 | 0 | 0 | For |
| Invesco | 0 | 347,469 | 0 | 0 | Against |
| Equitable | 190,328 | 109,540 | 0 | 0 | Mixed |
| TIAA | 0 | 271,483 | 0 | 0 | Against |
| Dimensional | 0 | 255,844 | 0 | 0 | Against |
| AQR | 0 | 194,978 | 0 | 0 | Against |
| BRIDGEWAY FUNDS INC | 0 | 185,000 | 0 | 0 | Against |
| QUANTITATIVE MASTER SERIES LLC | 177,479 | 0 | 0 | 0 | For |
| Goldman Sachs | 0 | 166,654 | 0 | 0 | Against |
| Lincoln Financial | 0 | 78,044 | 0 | 0 | Against |
| Northern Trust | 0 | 61,862 | 0 | 0 | Against |
| MASTER INVESTMENT PORTFOLIO | 58,263 | 0 | 0 | 0 | For |
| Global X | 51,084 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 45,952 | 0 | 0 | 0 | For |
| Pacific Life | 43,851 | 0 | 0 | 0 | For |
| Nationwide | 35,680 | 0 | 0 | 0 | For |
| Thrivent | 0 | 33,153 | 0 | 0 | Against |
| Blackstone Alternative Investment Funds | 0 | 25,500 | 0 | 0 | Against |
| Voya | 0 | 22,502 | 0 | 0 | Against |
| SEI | 18,600 | 0 | 0 | 0 | For |
| ProShares | 0 | 16,144 | 0 | 0 | Against |
Showing the 25 largest of 43 asset managers. All 43 are in the interactive database (link above).
Combines 9 wordings of this item as funds reported it.
97% Majority: yes · of votes cast
Prior year: 92.4% for (May 29, 2025 meeting) ▲ 4.7 pts
Description as filed by funds: To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy statement.
Fate Therapeutics, Inc.’s own tally for this item (“(iii) Non-binding advisory vote on the compensation of the Company's named executive officers.”): 59,168,689 for, 1,808,669 against, per its Form 8-K filed June 15, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,344,541 | 5 | 0 | 0 | For |
| BlackRock | 4,292,201 | 0 | 0 | 0 | For |
| Fidelity | 2,222,049 | 0 | 0 | 0 | For |
| BRUCE FUND INC | 789,188 | 0 | 0 | 0 | For |
| Charles Schwab | 756,976 | 0 | 0 | 0 | For |
| Invesco | 347,469 | 0 | 0 | 0 | For |
| Equitable | 299,868 | 0 | 0 | 0 | For |
| TIAA | 271,483 | 0 | 0 | 0 | For |
| Dimensional | 255,844 | 0 | 0 | 0 | For |
| AQR | 194,978 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 0 | 185,000 | 0 | 0 | Against |
| QUANTITATIVE MASTER SERIES LLC | 177,479 | 0 | 0 | 0 | For |
| Goldman Sachs | 166,654 | 0 | 0 | 0 | For |
| Lincoln Financial | 78,044 | 0 | 0 | 0 | For |
| Northern Trust | 0 | 61,862 | 0 | 0 | Against |
| MASTER INVESTMENT PORTFOLIO | 58,263 | 0 | 0 | 0 | For |
| Global X | 51,084 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 45,952 | 0 | 0 | 0 | For |
| Pacific Life | 43,851 | 0 | 0 | 0 | For |
| Nationwide | 35,680 | 0 | 0 | 0 | For |
| Thrivent | 33,153 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 25,500 | 0 | 0 | 0 | For |
| Voya | 22,502 | 0 | 0 | 0 | For |
| SEI | 18,600 | 0 | 0 | 0 | For |
| ProShares | 16,144 | 0 | 0 | 0 | For |
Fund voting reports, all 43 managers: 18,673,312 for, 246,867 against. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Redmile Group, LLC | 12,872,946 | 0 | 0 | 0 | For |
| BlackRock | 4,091,262 | 194 | 0 | 0 | For |
| ACADIAN ASSET MANAGEMENT LLC | 3,029,747 | 51,458 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 2,590,429 | 0 | 0 | 0 | For |
| AQR | 1,699,426 | 0 | 0 | 0 | For |
| State Street | 1,476,329 | 5,160 | 0 | 0 | For |
| Two Sigma | 992,688 | 0 | 0 | 0 | For |
| Irenic Capital Management LP | 878,053 | 0 | 0 | 0 | For |
| Invesco | 802,446 | 0 | 0 | 0 | For |
| Charles Schwab | 757,383 | 0 | 0 | 0 | For |
| Vanguard | 724,306 | 0 | 0 | 0 | For |
| DAFNA Capital Management LLC | 550,000 | 0 | 0 | 0 | For |
| Renaissance | 518,788 | 0 | 0 | 0 | For |
| Connor, Clark & Lunn Investment Management Ltd. | 471,958 | 0 | 0 | 0 | For |
| Northern Trust | 4,108 | 403,931 | 0 | 0 | Against |
| MELLON INVESTMENTS Corp | 374,329 | 0 | 0 | 0 | For |
| Nuveen | 339,073 | 0 | 0 | 0 | For |
| Citadel | 324,943 | 0 | 0 | 0 | For |
| Man Group plc | 303,587 | 0 | 0 | 0 | For |
| AllianceBernstein | 187,760 | 0 | 0 | 0 | For |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0 | 185,000 | 0 | 0 | Against |
| T. Rowe Price | 132,998 | 0 | 0 | 0 | For |
| Goldman Sachs | 127,997 | 0 | 0 | 0 | For |
| National Philanthropic Trust | 0 | 0 | 0 | 0 | Not Voted |
| Dimensional | 90,698 | 0 | 0 | 0 | For |
Institutional-manager reports, all 112 managers: 34,287,068 for, 772,933 against, 4,500 abstained, 128,000 not voted. Showing the 25 largest; every one is in the interactive database (link above).
99.6% Majority: yes · of votes cast
Prior year: 99.3% for (May 29, 2025 meeting) ▲ 0.3 pts
Description as filed by funds: TO APPROVE THE RATIFICATION OF ERNST & YOUNG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPANY FOR ITS FISCAL YEAR ENDING DECEMBER 31, 2026.
Fate Therapeutics, Inc.’s own tally for this item (“(ii) Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.”): 86,552,927 for, 308,582 against, per its Form 8-K filed June 15, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.6% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 43 asset managers below reported 18,920,180 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 8,344,547 | 0 | 0 | 0 | For |
| BlackRock | 4,292,201 | 0 | 0 | 0 | For |
| Fidelity | 2,222,049 | 0 | 0 | 0 | For |
| BRUCE FUND INC | 789,188 | 0 | 0 | 0 | For |
| Charles Schwab | 756,976 | 0 | 0 | 0 | For |
| Invesco | 347,469 | 0 | 0 | 0 | For |
| Equitable | 299,868 | 0 | 0 | 0 | For |
| TIAA | 271,483 | 0 | 0 | 0 | For |
| Dimensional | 255,844 | 0 | 0 | 0 | For |
| AQR | 194,978 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 185,000 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 177,479 | 0 | 0 | 0 | For |
| Goldman Sachs | 166,654 | 0 | 0 | 0 | For |
| Lincoln Financial | 78,044 | 0 | 0 | 0 | For |
| Northern Trust | 61,862 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 58,263 | 0 | 0 | 0 | For |
| Global X | 51,084 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 45,952 | 0 | 0 | 0 | For |
| Pacific Life | 43,851 | 0 | 0 | 0 | For |
| Nationwide | 35,680 | 0 | 0 | 0 | For |
| Thrivent | 33,153 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 25,500 | 0 | 0 | 0 | For |
| Voya | 22,502 | 0 | 0 | 0 | For |
| SEI | 18,600 | 0 | 0 | 0 | For |
| ProShares | 16,144 | 0 | 0 | 0 | For |
Showing the 25 largest of 43 asset managers. All 43 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 116,272,513 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 7.18% |
| 2 | BlackRock | 3.69% |
| 3 | Fidelity | 1.91% |
| 4 | BRUCE FUND INC | 0.68% |
| 5 | Charles Schwab | 0.65% |
| 6 | Invesco | 0.30% |
| 7 | Equitable | 0.26% |
| 8 | TIAA | 0.23% |
| 9 | Dimensional | 0.22% |
| 10 | AQR | 0.17% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Redmile Group, LLC | 11.07% |
| 2 | BlackRock | 3.52% |
| 3 | ACADIAN ASSET MANAGEMENT LLC | 2.65% |
| 4 | GEODE CAPITAL MANAGEMENT, LLC | 2.23% |
| 5 | AQR | 1.46% |
| 6 | State Street | 1.27% |
| 7 | Two Sigma | 0.85% |
| 8 | Irenic Capital Management LP | 0.76% |
| 9 | Invesco | 0.69% |
| 10 | Charles Schwab | 0.65% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| Redmile Group, LLC | 18,229,078 | 15.68% | Schedule 13D, filed April 22, 2026 |
| Entities affiliated with Redmile Group, LLC | 12,872,946 | 11.07% | Proxy statement (DEF 14A), table as of March 31, 2026 |
| ARK Investment Management LLC | 10,312,167 | 8.87% | Proxy statement (DEF 14A), table as of March 31, 2026 |
| BlackRock | 10,068,614 | 8.66% | Form 13F, quarter ended March 31, 2026 |
| Vanguard Group | 8,971,347 | 7.72% | Form 13F, quarter ended March 31, 2026 |
| Two Sigma | 3,466,786 | 2.98% | Form 13F, quarter ended March 31, 2026 |
| AQR Capital | 3,001,521 | 2.58% | Form 13F, quarter ended March 31, 2026 |
| Renaissance Technologies | 2,974,683 | 2.56% | Form 13F, quarter ended March 31, 2026 |
| Geode Capital | 2,590,429 | 2.23% | Form 13F, quarter ended March 31, 2026 |
| State Street | 2,263,173 | 1.95% | Form 13F, quarter ended March 31, 2026 |
Percentages above are of 116,272,513 shares outstanding, as reported by Fate Therapeutics, Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At Fate Therapeutics, Inc.'s shareholder meeting held June 12, 2026, in the 2025-2026 proxy season, 140 asset managers reported votes on at least one of its 6 ballot items in their SEC Form N-PX filings, covering 905 separate fund positions. On the most widely held item on that ballot — To approve, on a non-binding advisory basis, the compensation of the Company's named executive… — FOR was 97% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Fate Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 15, 2026.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Fate Therapeutics, Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
Fate Therapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
Proxy Votes Now, “Fate Therapeutics (FATE) 2026 Annual Meeting: Shareholder Vote Results”, https://proxyvotesnow.com/company/fate-therapeutics-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.